Janet L Kwiatkowski1, Eunsil Yim, Scott Miller, Robert J Adams. 1. Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA. kwiatkowski@email.chop.edu
Abstract
BACKGROUND: Children with sickle cell disease (SCD) and abnormal transcranial Doppler (TCD) ultrasonography have a high risk of stroke, but this risk is greatly reduced when chronic transfusion therapy is administered. The change in TCD velocities during chronic transfusion therapy and rate and frequency of normalization of TCD findings have not been studied extensively. PROCEDURES: Using data from children with SCD enrolled as potential subjects in the Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) trial, we characterized the change in TCD velocities on transfusion therapy and identified predictors of developing a normal TCD. RESULTS: Among 88 children with serial TCD data after starting transfusions for abnormal TCD 46 (52%) converted to normal TCD after a mean of 4.3 months (median 3.0; range 0.85-14.3 months) of transfusions. TCD studies remained abnormal in 19/88 (21.6%) after a mean of 2.4 years of transfusion. The median TCD velocity was lowered by 38 cm/sec within 3 months of initiating transfusions, followed by a more gradual decline then stabilization of velocities, although with significant individual variation. Factors associated with conversion to normal TCD included lower initial TCD velocity, younger age, and higher pre-transfusion hemoglobin level during transfusion therapy. CONCLUSION: Younger children with higher pre-transfusion hemoglobin levels and lower abnormal TCD velocities are most likely to have rapid normalization of TCD on transfusions. Long-term follow-up of children with persistently abnormal exams or worsening velocities on transfusion is needed to determine if these children are at higher risk of stroke.
BACKGROUND:Children with sickle cell disease (SCD) and abnormal transcranial Doppler (TCD) ultrasonography have a high risk of stroke, but this risk is greatly reduced when chronic transfusion therapy is administered. The change in TCD velocities during chronic transfusion therapy and rate and frequency of normalization of TCD findings have not been studied extensively. PROCEDURES: Using data from children with SCD enrolled as potential subjects in the Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) trial, we characterized the change in TCD velocities on transfusion therapy and identified predictors of developing a normal TCD. RESULTS: Among 88 children with serial TCD data after starting transfusions for abnormal TCD 46 (52%) converted to normal TCD after a mean of 4.3 months (median 3.0; range 0.85-14.3 months) of transfusions. TCD studies remained abnormal in 19/88 (21.6%) after a mean of 2.4 years of transfusion. The median TCD velocity was lowered by 38 cm/sec within 3 months of initiating transfusions, followed by a more gradual decline then stabilization of velocities, although with significant individual variation. Factors associated with conversion to normal TCD included lower initial TCD velocity, younger age, and higher pre-transfusion hemoglobin level during transfusion therapy. CONCLUSION: Younger children with higher pre-transfusion hemoglobin levels and lower abnormal TCD velocities are most likely to have rapid normalization of TCD on transfusions. Long-term follow-up of children with persistently abnormal exams or worsening velocities on transfusion is needed to determine if these children are at higher risk of stroke.
Authors: R J Adams; V C McKie; E M Carl; F T Nichols; R Perry; K Brock; K McKie; R Figueroa; M Litaker; S Weiner; D Brambilla Journal: Ann Neurol Date: 1997-11 Impact factor: 10.422
Authors: Margaret T Lee; Sergio Piomelli; Suzanne Granger; Scott T Miller; Shannon Harkness; Donald J Brambilla; Robert J Adams Journal: Blood Date: 2006-08-01 Impact factor: 22.113
Authors: R Adams; V McKie; F Nichols; E Carl; D L Zhang; K McKie; R Figueroa; M Litaker; W Thompson; D Hess Journal: N Engl J Med Date: 1992-02-27 Impact factor: 91.245
Authors: R J Adams; V C McKie; L Hsu; B Files; E Vichinsky; C Pegelow; M Abboud; D Gallagher; A Kutlar; F T Nichols; D R Bonds; D Brambilla Journal: N Engl J Med Date: 1998-07-02 Impact factor: 91.245
Authors: Najibah A Galadanci; Shehu U Abdullahi; Musa A Tabari; Shehi Abubakar; Raymond Belonwu; Auwal Salihu; Kathleen Neville; Fenella Kirkham; Baba Inusa; Yu Shyr; Sharon Phillips; Adetola A Kassim; Lori C Jordan; Muktar H Aliyu; Brittany V Covert; Michael R DeBaun Journal: Pediatr Blood Cancer Date: 2014-11-14 Impact factor: 3.167
Authors: Michael R Debaun; Najibah A Galadanci; Adetola A Kassim; Lori C Jordan; Sharon Phillips; Muktar H Aliyu Journal: Trans Am Clin Climatol Assoc Date: 2016
Authors: Ann T Farrell; Julie Panepinto; C Patrick Carroll; Deepika S Darbari; Ankit A Desai; Allison A King; Robert J Adams; Tabitha D Barber; Amanda M Brandow; Michael R DeBaun; Manus J Donahue; Kalpna Gupta; Jane S Hankins; Michelle Kameka; Fenella J Kirkham; Harvey Luksenburg; Shirley Miller; Patricia Ann Oneal; David C Rees; Rosanna Setse; Vivien A Sheehan; John Strouse; Cheryl L Stucky; Ellen M Werner; John C Wood; William T Zempsky Journal: Blood Adv Date: 2019-12-10
Authors: Najibah A Galadanci; Shehu Umar Abdullahi; Leah D Vance; Abdulkadir Musa Tabari; Shehi Ali; Raymond Belonwu; Auwal Salihu; Aisha Amal Galadanci; Binta Wudil Jibir; Halima Bello-Manga; Kathleen Neville; Fenella J Kirkham; Yu Shyr; Sharon Phillips; Brittany V Covert; Adetola A Kassim; Lori C Jordan; Muktar H Aliyu; Michael R DeBaun Journal: Am J Hematol Date: 2017-06-15 Impact factor: 10.047
Authors: Jon A Detterich; Suvimol Sangkatumvong; Roberta Kato; Ani Dongelyan; Adam Bush; Michael Khoo; Herbert J Meiselman; Thomas D Coates; John C Wood Journal: Transfusion Date: 2012-11-26 Impact factor: 3.157